Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection—United States, 2012–2016
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.